TAK-457

structure in first source

Networked: 1 relevant articles (1 outcomes, 0 trials/studies)

1.	Invasive Pulmonary Aspergillosis 02/01/2002 - "Efficacy of TAK-457, a novel intravenous triazole, against invasive pulmonary Aspergillosis in neutropenic mice." 02/01/2002 - "The in vivo efficacy of TAK-457 was evaluated in two models of invasive pulmonary aspergillosis with CDF(1) mice and CBA/J mice with transient neutropenia induced by cyclophosphamide. "
2.	Neutropenia 02/01/2002 - "The in vivo efficacy of TAK-457 was evaluated in two models of invasive pulmonary aspergillosis with CDF(1) mice and CBA/J mice with transient neutropenia induced by cyclophosphamide. "
3.	Infections 02/01/2002 - "Against the infection in CDF(1) mice, treatment with 10 mg of TAK-457 and 1 mg of amphotericin B/kg reduced the fungal burden in lungs and rescued all mice. " 02/01/2002 - "In the infection model with CBA/J mice, TAK-457 at a dose of 10 mg/kg significantly prolonged the survival time of mice, showing significant reduction of lung chitin levels and the plasma beta-D-glucan levels. "
4.	Aspergillosis 02/01/2002 - "These results suggest that TAK-457 is a promising candidate for development for the treatment of invasive aspergillosis in humans."

1.	Triazoles
2.	Cyclophosphamide (Cytoxan)
3.	Chitin
4.	polyglucosan
5.	Amphotericin B (Amphotericin)